NH2-terminally modified gastric inhibitory polypeptide exhibits amino- peptidase resistance and enhanced antihyperglycemic activity

Diabetes

Volumn 48, Issue 4, 1999, Pages 758-765

  O'Harte, Finbarr P M ^a   Mooney, Mark H ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; DIPEPTIDYL PEPTIDASE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INSULIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV;

ARTICLE; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INACTIVATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; HORMONAL REGULATION; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; HOMEOSTASIS; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; PLASMA; WISTAR RAT;

AMINOPEPTIDASES; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DRUG RESISTANCE; GASTRIC INHIBITORY POLYPEPTIDE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PLASMA; RATS; RATS, WISTAR; SPECTROMETRY, MASS, SECONDARY ION;

EID: 0032587206     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.4.758     Document Type: Article

References (55)

1. Brown JC: Enteroinsular axis. In Gut Peptides Biochemishy and Physiology. Walsh JH, Dockray GJ, Eds, New York, Raven Press, 1994, p. 765-784
2. Herrmann C, Göke R, Richter G, Fehmann H-C, Arnold R, Göke B: Glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide plasma levels in response to nutrients. Digestion 56:117-126; 1995
3. Creutzfeldt W: The incretin concept today. Diabetologia 16:75-85, 1979
4. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
5. Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
6. Schmidt WE, Siegel EG, Kummel H, Gallwitz B, Creutzfeldt W: Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39. Endocrinology 120:835-837, 1987
7. Gefel D, Hendrick GK, Mojsov S, Habener J, Weir GC: Glucagon-like peptide-1 analogs: effects on insulin secretion and 3′,5′-monophosphate formation. Endocrinology 126:2164-2168, 1990
8. Grandt D, Sieburg B, Schimiczek M, Becker U, Holtmann G, Layer P, Reeve JR, Eysselein VE, Goebell H, Müeller M: Is GLP-1(9-36)amide an endogenous antagonist at GLP-1 receptors? (Abstract) Digestion 55:302A, 1994
9. 142 action in vitro. Regul Pept 69:151-154, 1997
10. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
11. Ørskov C, Wettergren A, Holst JJ: The metabolic rate and the biological effects of GLP-1 7-36 amide and GLP-1 7-37 in healthy volunteers are identical. Diabetes 42:658-661, 1993
12. Pederson RA: Gastric inhibitory polypeptide. In Gut Peptides Biochemistry and Physiology. Walsh JH, Dockray GJ, Eds. New York, Raven Press, 1994, p. 217-259
13. Byrne MM, Göke B: Lessons from human studies with glucagon-like peptide-1: potential of the gut hormone for clinical use. In The Insulinotropic Gut Hormone Glucagon-Like Peptide-1. Fehmann HC, Göke B, Eds. Basel, Switzerland, Karger, 1997, p. 219-233
14. Ritzel R, Ørskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1(7-36)amide after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38:720-725, 1995
15. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic patients. Diabetes Care 15:270-276, 1992
16. Rose CA, Kim Y: Precipitation of insulinotropin in the presence of protamine: effect of phenol and zinc on the isophane ratio and the insulinotropin in the supernatant. Pharmacol Res 12:1284-1288, 1995
17. Deacon CF, Hughes TE, Holst JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anaesthesised pig. Diabetes 47:764-769, 1998
18. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Demuth H-U: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258, 1998
19. Holst JJ, Deacon CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670, 1998
20. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1326-1322, 1992
21. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willims B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide-1(7-36) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
22. Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke G: Glucagon-like peptide-1 improves the ability of the β-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes 47:1259-1265, 1998
23. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC, Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
24. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
25. Deacon CF, Knudsen LB, Madsen K, Wilberb FC, Jacobsen O, Holst JJ: Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278, 1998
26. Mooney MH, O'Harte FPM, Flatt PR: Aminopeptidase resistant glycated glucagon-like peptide-1(7-36)amide shows potent insulinotropic action in vivo (Abstract). Diabetologia 41 (Suppl. 1):A183, 1998
27. Thorens B, Dolci W, Burcelin R: Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analogue of GLP-1 (Abstract). Diabetologia 41 (Suppl. 1): A183, 1998
28. O'Harte FPM, Abdel-Wahab YHA, Conlon JM, Flatt PR: Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells. Diabetologia 41:1167-1193, 1998
29. Pederson RA, Satkunarajah M, McIntosh CHS, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, Wheeler MB: Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/-mice. Diabetes 47:1046-1052, 1998
30. Elahi D, Andersen DK, Brown JC, Debas H, Hershcopf RJ, Raizes GS, Tobin JD, Andres R: Pancreatic α- and β-cell responses to GIP infusion in normal man. Am J Physiol 237:185-191, 1979
31. Marks V, Morgan LM: Intra-islet interactions and the enteroinsular axis in insulin secretion. In Frontiers of Insulin Secretion and Pancreatic β-Cell Research. Flatt PR, Lenzen S, Eds. London, Smith-Gordon, 1994, p. 319-324
32. O'Harte FPM, Abdel-Wahab YHA, Conlon JM, Flatt PR: Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochem Biophys Acta 1425:319-327, 1998
33. Stevens VJ: Determination of glucose by automatic analyser. Clin Chem 32:9199-9201, 1971
34. Flatt PR, Bailey CJ: Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20:573-577, 1981
35. Burington RS, Ed.: Handbook of Mathematical Tables and Formulas. New York, McGraw-Hill, 1973
36. Buchan AMJ, Polak JM, Capella C, Solcia E, Pearse AGE: Electron immunocytochemical for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry 546:37-44, 1978
37. Sykes S, Morgan LM, English J, Marks V: Evidence for preferential stimulation of gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates and their analogues. J Endocrinol 85:201-207, 1980
38. Kwasowski P, Flatt PR, Bailey CJ, Marks V: Effect of fatty acid chain length and saturation on gastric inhibitory peptide release in obese hyperglycaemic (ob/ob) mice. Biosci Rep 5:701-705, 1985
39. Flatt PR, Kwasowski P, Howland RJ, Bailey CJ: Gastric inhibitory polypeptide and insulin responses to orally administered amino acids in genetically obese hyperglycaemic (ob/ob) mice. J Nutr 121:1123-1128, 1991
40. Pederson RA, Brown JC: The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99:780-785, 1976
41. Bailey CJ, Flatt PR: Development of antidiabetic drugs. In Drugs, Diet and Disease, Vol. 2, Mechanistic Approaches to Diabetes. Ioannides C, Flatt PR, Eds. London, Ellis Horwood, 1995, p. 279-326
42. Pauly RP, Rosche F, Wermann M, McIntosh CHS, Pederson RA, Demuth HU: Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidylpeptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. J Biol Chem 271:23222-23229, 1996
43. Maletti M, Carlquist M, Portha B, Kergoat M, Mutt V, Rosselin G: Structural requirements for gastric inhibitory polypeptide (GIP) receptor binding and stimulation of insulin release. Peptides 7:75-78, 1986
44. Oektedalen O, Opstad PK, Jorde R: Increased plasma response of gastric inhibitory polypeptide to oral glucose and a liquid meal after prolonged starvation in healthy man. Digestion 26:114-123, 1983
45. Moody AJ, Damm Jorgensen K, Thim L: Structure-function relationships in porcine GIP (Abstract). Diabetologia 21:306, 1981
46. Eckel RH, Fujimoto WJ, Brunzell JD: Gastric inhibitory polypeptide enhances lipoprotein lipase activity incultured pre-adipocytes. Diabetes 28:1141-1142, 1978
47. Morgan LM: The metabolic role of GIP: physiology and pathology. Biochem Soc Trans 24:585-591, 1996
48. Oben J, Morgan L, Fletcher J, Marks V: Effect of the entero-pancreatic hormones gastric inhibitory polypeptide and glucagon-like peptide-1(7-36)amide on tally acid synthesis in explants of rat adipose tissue. J Endocrinol 130:267-272, 1991
49. Ebert R, Nuack M, Creutzfeldt W: Effects of exogenous and endogenous gastric inhibitory polypeptide on plasma triglyceride responses in rats. Horm Metab Res 23:517-521, 1991
50. Elahi D, Meneilly GS, Minaker KL, Rowe JW, Andersen DK: Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. In Proceedings of Sixth International Conference on Gastrointestinal Hormones. Vancouver, National Research Council of Canadian Research Journals, 1986, p. 18
51. Hartmann H, Ebert R, Creutzfeldt W: Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver. Diabetologia 29:112-114, 1986
52. O'Harte FPM, Gray AM, Flatt PR: Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J Endocrinol 156:237-243, 1998
53. Villanueva-Peñacarrillo, ML, Alcántara AI, Clemente F, Delgado E, Valverde I: Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37:1163-1166, 1994
54. O'Harte FPM, Gray AM, Abdel-Wahab YHA, Flatt PR: Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides 18:1327-1333, 1997
55. Wahren J, Efendic S, Luft R, Hagenfeldt L, Bjorkman O, Felig P: Influence of somatostatin on sphlachnic glucose metabolism in postabsorptive and 60-hour fasted humans. J Clin Invest 59:299-307, 1977